Building Blocks: Bulk Drugs, Excipients and Intermediates

The largest supplier of generic drugs globally, India continues to fortify its reputation as a hub for the production of affordable quality medicines. Catherine Howe India’s strength in pharmaceutical formulations depends on a high-quality, cost-efficient and reliable supply of the required raw materials and building blocks. Whilst India has strong capabilities in active pharmaceutical ingredients (APIs), the domestic market has become increasingly crowded, marked by a heavy reliance on imports from China. “India had to manufacture the drugs that were remunerative for the country,” exp...

India Pharmaceuticals 2017 Pre-Release

Country: India • Industry: Pharmaceuticals • Publication: Global Business Reports • Release Date: October 2017 • Authors: Catherine Howe, Neha Premjee Executive Summary: India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs globally and a proponent of high-quality affordable medicines. The industry has posted double-digit growth over the last few years, rising to US$36.7 billion and projected to grow to US$40 billion by 2020. However, as price erosion continues to impact the market and competition increases, many of...

Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, Information Technology, Electronics and Communication, Municipal Administration, Urban Development and NRI Affairs, Government of Telangana

GBR Connect Series Telangana State contains one of India’s most important life science clusters and its Government explains to GBR its plans to maintain the State’s rapid industrial growth. Telangana is India’s youngest state, formed only in 2014. How has the state developed to the present day? Being the youngest makes Telangana the most energetic too. The state achieved GSDP growth of 10.1% in 2016 to 2017, which is higher than the national growth, and the share of Telangana’s economy in national GDP has increased by seven basis points in 2016 to 2017. Our new industrial policy, whic...

Érica Takeda, Managing Director, Brenntag

GBR Connect Series Brenntag in Brazil is determined to continue its expansion through acquisitions. Could you introduce Brenntag’s Brazil operations and the impact of the recent Gafor Distribuidora acquisition (2014)? Brenntag started in Brazil through acquisitions, which is how most global distributors started developing their networks in emerging markets. The acquisition of Gafor Distribuidora was aimed at bringing some of ExxonMobil Chemical’s solvents and other specialty products into our portfolio and reflects Brenntag´s goal to continuously optimize our product portfolio in line wi...

    Anil Jain, Director, S.A. Pharmachem

    S. A. Pharmachem is a specialty food and pharmaceutical manufacturing and marketing company supplying innovative specialty ingredients. S.A. Pharmachem reached its 30th anniversary last year. How has the company grown and developed over the years? S.A. Pharmachem grew 28% to 30% over the last year alone. Together with Gangwal Chemicals, we had a joint turnover of around US$37.6 million in 2016, while 2015’s turnover was around US$2.9 million. S. A. Pharmachem focuses on nutraceutical actives and a few pharmaceutical actives. Meanwhile, Gangwal focuses on pharmaceutical excipients, drug d...

    Reinaldo Kröger, President and Edson de Paiva, Operations Director, Unigel

    GBR Connect Series Unigel is Latin America’s leading producer of acrylics and styrenics What are Unigel’s main focus areas currently? RK: We are currently investing US$90 million to increase our styrene capacity by 35,000 tonnes per year (mt/y) in time for the first quarter of 2018 and 65,000 mt/y by 2020. This means we will have 400,000 mt/y capacity for styrene monomer along with 320,000 mt/y for polystyrene by 2020. Alongside increasing production, we also aim to reduce energy costs and modernise our facilities. Another key development is Unigel’s purchase this year of the latex div...

    N. R. Munjal, Vice Chairman and Managing Director, Ind-Swift Laboratories Ltd & Vice-Chairman, Ind-Swift Ltd.

    GBR Connect Series Ind-Swift is a pharmaceutical manufacturing and marketing company based in Chandigarh with its strength in innovative pharmaceutical products. Ind-Swift has now surpassed its 30th year of operation and ranks within the Top 50 Indian pharmaceutical companies. How has the company developed over the years, and what has been the key to its success? The group consists of two companies: Ind-Swift Laboratories (ISLL), which manufatures and markets APIs and advanced intermediates, and Ind-Swift Ltd. (ISL) which manufactures and markets finished dosage forms (FDFs). Beginning wit...

    Edison Terra Filho, Executive Vice President, Braskem

    GBR Connect Series Braskem is a global petrochemical company with a Brazilian heart. What has been the evolution of Braskem over the last years? Braskem is a global petrochemical company with a Brazilian heart. It started in 2002 from the merger of six different companies and it consolidated its Brazilian industry in 2010. In parallel to that, the company acquired Sunoco’s and Dow’s polypropylene (PP) businesses, with units in the U.S. and Germany. After that, Braskem also made a brand new investment of US$5.2 billion in Mexico, which came on stream last year, in the form of a joi...

    GV Sanjay Reddy, Vice Chairman, GVK

    GVK is a leader in infrastructure development and recently constructed Mumbai’s much acclaimed new airport. Since its establishment in 1992, GVK has played a key role in underpinning India’s growth through its infrastructure development. How has the company developed itself? GVK has been a leader in infrastructure development in India since 1992. We set up India’s first independent power project, a gas-based project in the state of Andhra Pradesh and started construction in 1994, going into operation in 1996. Since then we have expanded our presence in power – gas, coal and hydro...

    More articles